$34.29 Million in Sales Expected for Heska Corp (NASDAQ:HSKA) This Quarter

Wall Street analysts forecast that Heska Corp (NASDAQ:HSKA) will post sales of $34.29 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heska’s earnings. The highest sales estimate is $34.36 million and the lowest is $34.21 million. Heska reported sales of $34.06 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 0.7%. The company is expected to announce its next quarterly earnings results on Tuesday, February 25th.

On average, analysts expect that Heska will report full-year sales of $123.18 million for the current year, with estimates ranging from $123.11 million to $123.25 million. For the next fiscal year, analysts anticipate that the firm will report sales of $140.02 million, with estimates ranging from $138.76 million to $141.27 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Heska.

Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04). Heska had a return on equity of 3.17% and a net margin of 3.15%. The business had revenue of $31.24 million during the quarter, compared to analyst estimates of $30.44 million.

A number of equities analysts have weighed in on the company. Raymond James lowered Heska from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. They noted that the move was a valuation call. BidaskClub raised Heska from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 27th. Canaccord Genuity reissued a “buy” rating and issued a $105.00 target price (up previously from $75.00) on shares of Heska in a research report on Wednesday, November 6th. Piper Jaffray Companies assumed coverage on Heska in a research report on Wednesday, September 18th. They issued a “neutral” rating and a $68.00 target price for the company. Finally, Zacks Investment Research lowered Heska from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $85.75.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HSKA. FMR LLC increased its position in shares of Heska by 2.0% during the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after purchasing an additional 8,870 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Heska during the 2nd quarter valued at about $852,000. NJ State Employees Deferred Compensation Plan increased its position in shares of Heska by 40.0% during the 2nd quarter. NJ State Employees Deferred Compensation Plan now owns 7,000 shares of the medical research company’s stock valued at $596,000 after purchasing an additional 2,000 shares during the last quarter. Arizona State Retirement System increased its position in shares of Heska by 2.7% during the 2nd quarter. Arizona State Retirement System now owns 10,821 shares of the medical research company’s stock valued at $922,000 after purchasing an additional 285 shares during the last quarter. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of Heska during the 2nd quarter valued at about $29,000. 97.92% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:HSKA traded up $0.81 during mid-day trading on Wednesday, reaching $96.10. The company’s stock had a trading volume of 71,199 shares, compared to its average volume of 88,808. Heska has a 12-month low of $62.47 and a 12-month high of $104.05. The firm’s fifty day moving average price is $86.39 and its two-hundred day moving average price is $78.24. The company has a current ratio of 8.52, a quick ratio of 6.80 and a debt-to-equity ratio of 0.31. The stock has a market cap of $747.61 million, a P/E ratio of 67.68 and a beta of 1.08.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Featured Article: Quick Ratio

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.